Collectively, our data derived from transplant models, as well as autochthonous SCLC models, indicate that cell cycle checkpoint inhibition through ATR- and CHK1 inhibition displays selective therapeutic efficacy in murine SCLC tumors, compared to NSCLC tumors, in vivo. The gene discussed is ATR; the disease is small cell lung carcinoma.